Seegmiller A - Search Results

1

All in for patient safety: a team approach to quality improvement in our laboratories.

Weiss VL, Heher YK, Seegmiller A, VanderLaan PA, Nishino M. Weiss VL, et al. Among authors: seegmiller a. J Am Soc Cytopathol. 2022 Mar-Apr;11(2):87-93. doi: 10.1016/j.jasc.2021.12.001. Epub 2021 Dec 15. J Am Soc Cytopathol. 2022. PMID: 34996748 Free PMC article. Review.

2

Optimizing personalized bone marrow testing using an evidence-based, interdisciplinary team approach.

Seegmiller AC, Kim AS, Mosse CA, Levy MA, Thompson MA, Kressin MK, Jagasia MH, Strickland SA, Reddy NM, Marx ER, Sinkfield KJ, Pollard HN, Plummer WD, Dupont WD, Shultz EK, Dittus RS, Stead WW, Santoro SA, Zutter MM. Seegmiller AC, et al. Am J Clin Pathol. 2013 Nov;140(5):643-50. doi: 10.1309/AJCP8CKE9NEINQFL. Am J Clin Pathol. 2013. PMID: 24124142 Free PMC article.

3

Secondary-type mutations do not impact prognosis in acute myelogenous leukemia AML with mutated NPM1.

Wright MF, Pozdnyakova O, Hasserjian RP, Aggarwal N, Shaver AC, Weinberg OK, Irlmeier R, Koyama T, Seegmiller AC, Strickland SA, Mason EF. Wright MF, et al. Among authors: seegmiller ac. Am J Hematol. 2022 Dec;97(12):E462-E465. doi: 10.1002/ajh.26730. Epub 2022 Sep 30. Am J Hematol. 2022. PMID: 36106410 Free article. No abstract available.

4

A distinct immunophenotype identifies a subset of NPM1-mutated AML with TET2 or IDH1/2 mutations and improved outcome.

Mason EF, Kuo FC, Hasserjian RP, Seegmiller AC, Pozdnyakova O. Mason EF, et al. Am J Hematol. 2018 Aug;93(4):504-510. doi: 10.1002/ajh.25018. Epub 2018 Jan 25. Am J Hematol. 2018. PMID: 29274134 Free article.

5

Clinical Laboratory Experiences During the COVID-19 Pandemic.

Humphries R, Sefers S, Schmitz J, Seegmiller A. Humphries R, et al. Among authors: seegmiller a. Clin Infect Dis. 2024 May 15;78(5):1093-1096. doi: 10.1093/cid/ciad622. Clin Infect Dis. 2024. PMID: 37933663 No abstract available.

6

Limited utility of fluorescence in situ hybridization for common abnormalities of myelodysplastic syndrome at first presentation and follow-up of myeloid neoplasms.

Seegmiller AC, Wasserman A, Kim AS, Kressin MK, Marx ER, Zutter MM, Mosse CA. Seegmiller AC, et al. Leuk Lymphoma. 2014 Mar;55(3):601-5. doi: 10.3109/10428194.2013.801470. Epub 2013 Aug 28. Leuk Lymphoma. 2014. PMID: 23876099

7

CD30 expression and its correlation with MYC rearrangement in de novo diffuse large B-cell lymphoma.

Wang XJ, Seegmiller AC, Reddy NM, Li S. Wang XJ, et al. Eur J Haematol. 2016 Jul;97(1):39-47. doi: 10.1111/ejh.12680. Epub 2015 Oct 1. Eur J Haematol. 2016. PMID: 26340843

8

Increased MYC copy number is an independent prognostic factor in patients with diffuse large B-cell lymphoma.

Quesada AE, Medeiros LJ, Desai PA, Lin P, Westin JR, Hawsawi HM, Wei P, Tang G, Seegmiller AC, Reddy NM, Yin CC, Wang W, Xu J, Miranda RN, Zuo Z, Li S. Quesada AE, et al. Among authors: seegmiller ac. Mod Pathol. 2017 Dec;30(12):1688-1697. doi: 10.1038/modpathol.2017.93. Epub 2017 Aug 4. Mod Pathol. 2017. PMID: 28776574 Free article.

9

Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Shaver AC, Seegmiller AC. Shaver AC, et al. Curr Hematol Malig Rep. 2017 Oct;12(5):448-454. doi: 10.1007/s11899-017-0405-y. Curr Hematol Malig Rep. 2017. PMID: 28822050 Review.

10

Limited Utility of Fluorescence In Situ Hybridization for Recurrent Abnormalities in Acute Myeloid Leukemia at Diagnosis and Follow-up.

Wheeler FC, Kim AS, Mosse CA, Shaver AC, Yenamandra A, Seegmiller AC. Wheeler FC, et al. Among authors: seegmiller ac. Am J Clin Pathol. 2018 Mar 29;149(5):418-424. doi: 10.1093/ajcp/aqy002. Am J Clin Pathol. 2018. PMID: 29538617 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

61 results

Search Page